Thero2-01S22 / Strasbourg Europe Cancer Institute - LARVOL DELTA

2022-009: A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast CancernTherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study (clinicaltrialsregister.eu) - P2/3 | N=224 | Not yet recruiting | Sponsor: Centre Regional Lutte Contre Le Cancer

New P2/3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor